Consolidated Statements of Mezzanine Equity and Stockholders' Deficiency - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Shares to be Issued [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total	Series B Convertible Redeemable Preferred Stock [Member]	Mezzanine Equity [Member]
Balance at Mar. 31, 2023	$ 7	$ 8,753	$ 24,999	$ 92,844,478	$ (152,797)	$ (112,570,825)	$ (19,845,385)
Temporary equity, shares at Mar. 31, 2023
Temporary equity, value at Mar. 31, 2023
Balance, shares at Mar. 31, 2023	6,305	8,752,510	3,955
Issuance of common shares to adjust for rounding effect of Reverse Split [Note 9]		$ 21		(21)
Issuance of common shares to adjust for rounding effect of Reverse Split, shares		20,846
Issuance of mezzanine equity [Note 9]								$ 1,860,554	1,860,554
Issuance of mezzanine equity [Note 9], shares								330
Issuance of common shares for private placement [Note 9]		$ 37		119,248			119,285
Issuance of common shares for private placement, shares		36,897
Issuance of warrants for brokers [Note 9]				141,070			141,070
Conversion of mezzanine equity into common shares [Note 9]		$ 612	$ 228,786	353,907			583,305
Conversion of mezzanine equity into common shares [Note 9], shares		612,062	320,321
Issuance of shares for services [Note 9]		$ 92	$ 15,280	100,755			116,127
Issuance of shares for services [Note 9], shares		92,125	20,000
Stock based compensation - ESOP [Note 9]				1,025,930			1,025,930
Translation adjustment					185,175		185,175
Net loss before dividends for the period						(14,094,283)	(14,094,283)
Preferred stock dividends						(834,677)	(834,677)
Issuance of warrants for private placement holders [Note 9]				1,137,716			1,137,716
Conversion of mezzanine equity into common shares, shares								(65)
Conversion of mezzanine equity into common shares								$ (371,634)	(371,634)
Balance at Mar. 31, 2024	$ 7	$ 9,515	$ 269,065	95,723,083	32,378	(127,499,785)	(31,465,737)
Temporary equity, shares at Mar. 31, 2024								265
Temporary equity, value at Mar. 31, 2024								$ 1,488,920	1,488,920
Balance, shares at Mar. 31, 2024	6,305	9,514,440	344,276
Issuance of mezzanine equity [Note 9]								$ 1,082,999	1,082,999
Issuance of mezzanine equity [Note 9], shares								220
Issuance of common shares from at-the-market transaction [Note 9]		$ 98		125,129			125,227
Issuance of common shares from at-the-market transaction [Note 9], shares		97,811
Conversion of mezzanine equity into common shares [Note 9]		$ 4,365	(288,786)	1,240,257			1,015,836	$ (571,630)	(571,630)
Conversion of mezzanine equity into common shares [Note 9], shares								(100)
Conversion of mezzanine equity into common shares [Note 9], shares		4,365,022
Conversion of preferred shares into common shares [Note 9]	$ (6)	$ 8,952		4,925,756			4,934,702
Conversion of preferred shares into common shares [Note 9], shares	(6,104)	8,952,170
Conversion of convertible notes into common shares [Note 9		$ 1,595	$ 259,245	2,107,338			2,431,178
Conversion of convertible notes into common shares [Note 9], shares		1,595,445	577,644
Issuance of shares for services [Note 9]		$ 717	$ (15,280)	335,446			$ 320,883
Issuance of shares for services [Note 9], shares		716,666					716,666
Issuance of shares for settlement of accounts payable [Note 9]		$ 1,000		989,408			$ 990,409
Issuance of shares for settlement of accounts payable [Note 9], shares		1,000,413
Stock based compensation - ESOP [Note 9]				1,461,698			1,461,698
Translation adjustment					113,414		113,414
Net loss before dividends for the period						(8,421,179)	(8,421,179)
Preferred stock dividends						(466,141)	(466,141)
Deemed Dividend						(3,054,680)	(3,054,680)
Balance at Mar. 31, 2025	$ 1	$ 26,243	$ 284,244	$ 106,971,115	$ 145,792	$ (139,441,785)	$ (32,014,390)
Temporary equity, shares at Mar. 31, 2025								385
Temporary equity, value at Mar. 31, 2025								$ 2,000,290	$ 2,000,290
Balance, shares at Mar. 31, 2025	201	26,241,967	581,599

BIOTRICITY INC. 10-K